Business Context and Reporting Period
vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and chronic diseases. Its lead candidate, cadisegliatin, is a liver-selective glucokinase activator currently in a Phase 3 trial (CATT1) for Type 1 diabetes. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.0 million |
| Net Loss (Attributable to vTv) | $(8.7) million | $(4.8) million | $(19.8) million | $(14.8) million |
| Net Loss Per Share (Basic/Diluted) | $(1.08) | $(0.88) | $(2.80) | $(2.70) |
| Operating Expenses | $10.7 million | $6.5 million | $24.9 million | $20.3 million |
| Cash and Cash Equivalents (End of Period) | $98.5 million | $41.6 million | $98.5 million | $41.6 million |
| Accumulated Deficit | $(319.6) million | $(296.1) million | $(319.6) million | $(296.1) million |
Liquidity & Debt: As of September 30, 2025, the company held $98.5 million in cash. Current liabilities totaled $10.2 million, including $328,000 in the current portion of notes payable. The company has no long-term debt obligations listed on the balance sheet other than notes payable.
Material Changes vs. Prior Period
- Financing Activity: In August 2025, the company completed a private placement raising approximately $80.0 million in gross proceeds through the sale of units (common stock, pre-funded warrants, and common warrants). This significantly increased cash reserves from $36.7 million at year-end 2024 to $98.5 million.
- Operating Expenses: Research and Development (R&D) expenses increased by 118% in Q3 2025 compared to Q3 2024 ($7.0M vs. $3.2M). This was driven by increased clinical study costs for cadisegliatin and a $1.0 million accrual for a milestone payment to Novo Nordisk related to the initiation of the Phase 3 trial.
- Revenue: The company reported zero revenue for the nine months ended September 30, 2025, compared to $1.0 million in the same period in 2024 (derived from a Newsoara license milestone).
- Equity Structure: MacAndrews & Forbes converted all 577,108 shares of Class B common stock to Class A common stock, resulting in vTv Therapeutics Inc. owning approximately 100% of the operating subsidiary (vTv LLC).
Outlook, Risks, and Management Commentary
- Clinical Progress: The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025. The company amended the CATT1 trial protocol to shorten the duration from 12 to 6 months, expecting top-line data in the second half of 2026. A Phase 2 trial for Type 2 diabetes in the Middle East is expected to begin in Q4 2025.
- Liquidity Status: Management concluded that the recent financing has eliminated the "substantial doubt" regarding the company's ability to continue as a going concern that was disclosed in the June 30, 2025 filing.
- Future Funding: The company anticipates needing substantial additional funding for future operations and clinical trials. It is evaluating strategies including direct equity investments and licensing programs.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital, and potential dilution from future equity offerings. The company has no product revenue and relies on financing and collaboration agreements.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $98.5 million cash balance to confirm the timeline for the next capital raise.
- CATT1 Trial Timeline: Confirm the revised schedule for the CATT1 Phase 3 trial and the expected date for top-line data (H2 2026).
- Warrant Liability: Review the fair value adjustments of warrant liabilities ($119k total) and the terms of the new warrants issued in the August 2025 private placement (exercise price $22.71).
- Milestone Obligations: Monitor the $1.0 million Novo Nordisk milestone accrual and potential future milestone payments up to $115 million depending on regulatory approvals.
- Going Concern: Note the reversal of the "substantial doubt" disclosure from the previous quarter due to the successful $80M raise.